VISHEE(SH:688580) Zheng Quan Ri Bao Wang·2025-10-22 13:45Core Insights - Weisi Medical achieved a revenue of 326 million yuan in the first three quarters of 2025, representing a year-on-year growth of 11.58% [1] - The net profit attributable to shareholders reached 102 million yuan, with a year-on-year increase of 30.68% [1] - Operating cash flow net amount was 104 million yuan, showing a significant year-on-year growth of 69.02% [1] Quarterly Performance - In Q3 2025, Weisi Medical reported a revenue of 115 million yuan, reflecting a year-on-year growth of 14.87% [1] - The net profit attributable to shareholders for the quarter was 32.82 million yuan, with a year-on-year increase of 14.99% [1] - The operating cash flow net amount for Q3 was 39.62 million yuan, marking a year-on-year growth of 33.74% [1] Company Strategy and Technology - Weisi Medical is recognized as a national-level "specialized and innovative" small giant enterprise, leveraging six core technology platforms: magnetic stimulation, electrical stimulation, electrophysiology, robotics, laser, and radiofrequency [1] - The company focuses on three strategic areas: brain-computer interfaces, rehabilitation robots, and AI healthcare, aiming to create a new rehabilitation medical system that is precise, intelligent, and closed-loop [1] - Weisi Medical is committed to driving technological upgrades in the industry and transforming clinical paradigms through a comprehensive "diagnosis-treatment-rehabilitation" cycle [1] International Expansion - The company is accelerating its internationalization efforts by actively participating in international exhibitions and receiving positive market feedback [2] - With ongoing breakthroughs in product qualification for overseas markets, international business is expected to become a new growth engine for the company's performance in the medium to long term [2]